Abstract
Secondary (AA) amyloidosis is one of the most significant complications of ankylosing spondylitis (AS) that frequently leads to proteinuria and renal dysfunction. Anti-tumor necrosis factor alpha (anti-TNF) agents are promising in inducing clinical remission by suppressing systemic inflammation in AA amyloidosis. We report three cases with AS-related AA amyloidosis that responded well to etanercept therapy. Despite treatment with disease modifying anti-rheumatic drugs, all three patients had active AS, marked proteinuria, impaired renal function, and low serum albumin level. During 1-year treatment with etanercept, all patients experienced gradual improvement in all of these parameters.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Husby G (1992) Amyloidosis. Semin Arthritis Rheum 22:67–82
Buxbaum J (1998) The amyloidoses. In: Klippel JH, Dieppe PA (eds) Rheumatology, 2nd edn. Mosby, St. Louis, pp 5.24.7–10
Mladenovic J, Geisic L, Kerimovic D, Aramasic M, Merovic Z (1975) Incidence of amyloidosis in rheumatoid arthritis and ankylosing spondylitis. Scand J Rheumatol 4(Suppl 8):39
Hazenberg BP, van Rijswijk MH (1994) Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol 8:661–690
Hawkins PN (1997) Diagnosis and treatment of amyloidosis. Ann Rheum Dis 56:631–633
Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A, a major acute phase protein, in normal and disease states. Curr Opin Hematol 7:64–69
Yan SD, Zhu H, Zhu A et al (2000) Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6:643–651
Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H (2000) The receptor for advanced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κb and by 17β-estradiol through Sp-1in human vascular endothelial cells. J Biol Chem 33:25781–25790
Shibasaki T, Matsumoto H, Watabe K et al (1997) A case of renal amyloidosis associated with hepatic adenoma: the pathogenetic role of tumour necrosis factor-alpha. Nephron 75:350–353
Cunnane G, Whitehead AS (1999) Amyloid precursors and amyloidosis in rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 13:615–628
Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, Castro MC, Olive A, de Haro M, Garcia-Vicuna R, Gonzalez-Mari MV, Laffon A, Garcia-Vicuna R (2005) Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 118:552–556
Gottenberg JE, Merle-Vincent F, Bentaberry F et al (2003) Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 48:2019–2024
Drewe E, McDermott EM, Powell RJ (2000) Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome (letter). N Engl J Med 343:1044–1045
Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002) Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46:2571–2573
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kobak, S., Oksel, F., Kabasakal, Y. et al. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 26, 2191–2194 (2007). https://doi.org/10.1007/s10067-007-0679-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-007-0679-x